No ear­ly suc­cess for Re­gen­eron, Sanofi in PhI­II out­comes study for PC­SK9 drug Pralu­ent

Christ­mas is not com­ing ear­ly for Re­gen­eron and Sanofi.

The com­pa­nies not­ed ear­ly to­day that they will have to go all the way to the end of their out­comes tri­al to see if their PC­SK9 drug Pralu­ent can de­liv­er the goods in re­duc­ing the risk of a ma­jor car­dio event af­ter fail­ing to find over­whelm­ing ev­i­dence of suc­cess in its sec­ond pre­lim­i­nary re­view of the tri­al.

In­ves­ti­ga­tors re­cruit­ed 18,000 pa­tients with un­con­trolled LDL for the big tri­al, which will need to be pos­i­tive if they ever ex­pect to open up the mar­ket for their cho­les­terol drug. Pay­ers have dug their heels in on this drug, along with the ri­val Repatha from Am­gen, which just de­liv­ered fresh bio­mark­er da­ta to in­di­cate the like­li­hood of bend­ing the curve on ef­fi­ca­cy for an at-risk group of pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER